Back to News
Market Impact: 0.35
Anteris Receives German Regulatory Clearance For PARADIGM DurAVR Trial; Stock Up
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Anteris Technologies Global received full regulatory clearance from Germany’s BfArM to initiate the global PARADIGM pivotal trial of its DurAVR transcatheter device. The clearance enables the trial to begin; the article excerpt provides no further details on timing, enrollment, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AVR0.70
More News
- Jio’s Record $3.2 Billion IPO Puts India’s Market Muscle to the Test
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?
- Disc Medicine prices $450 million stock offering at $75/share
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Analyze SEC Filings With AI: A Verification-First Guide
- AI for IR Street Intelligence: Notes, Estimates, and Peers